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ABSTRACT 
Non-viral gene therapy is often proposed as an alternative to viral gene therapy, which is 
widely associated to safety concerns and elevated production costs. However, non-viral 
vectors suffer from limited transfection efficiency. The success of viruses in the delivery of 
the viral genome to target cells relies on the evolutionary selection of protein-based 
domains able to hijack the intermolecular interactions through which cells respond to intra- 
and extracellular stimuli. In an effort to mimic viral transfection capabilities, a modular 
recombinant protein named T-Rp3 was recently developed, containing a DNA binding 
domain, a dynein molecular motor interacting domain, and a TAT-derived transduction 
domain. Here, we analyzed at the microscopic level the mechanisms behind the cell 
internalization and intracellular trafficking of this efficient modular protein vector. We 
found that the protein has the ability to self-assemble in discrete protein nanoparticles 
resembling viral capsids, to bind and condense plasmid DNA (pDNA), and to interact with 
eukaryotic cell membranes. Confocal and single particle tracking assays performed on living 
HeLa cells revealed that the T-Rp3 vector promoted an impressive speed of cellular uptake 
and perinuclear accumulation, mainly due to interaction with microtubules and fast 
translocation towards the microtubule organizing center (MTOC). Finally, the protein 
demonstrated to be a versatile vector, delivering siRNA at efficiencies comparable to 
LipofectamineTM. The results presented here demonstrate the high potential of recombinant 
modular proteins with merging biological functions to fulfill several requirements needed 
to obtain cost-effective non-viral vectors for gene-based therapies through the rational 






Since the first gene therapy trial in 1990, more than 2,000 trials have been approved 
(http://www.abedia.com/wiley/). However, despite the great efforts made towards the 
development of gene therapies to replace faulty or missing genetic material in patient’s 
DNA, no single commercial product has been yet approved by the Food and Drug 
Administration (FDA) and only one has been granted by the European Medicines Agency 
(EMA) under the trade name Glybera (alipogen tiparvovec) [1,2]. Glybera is based on a non-
replicating adeno-associated virus designed to deliver a functional gene copy of the 
lipoprotein lipase gene. [3]. Other research products will probably be granted in the years 
to come provided preliminary data reveal their effectivity (Lentiglobin BB305 lentiviral 
vector, for instance) [4]. However, viral vectors are difficult to produce and purify at large 
scale. In addition, immunosuppression regimes have to be administered prior to the gene 
therapy treatment and their administration for a therapeutic approach entails 
environmental risks involved in using genetically modified replicative entities (Baldo et al., 
2013; Clement et al, 2010; Mingozzi and High, 2016). 
In this scenario, novel non-viral gene delivery strategies have been explored to deliver 
therapeutic nucleic acids. These vectors have to be designed to display the three basic 
characteristics of viral gene therapy vectors: 1) a potent nucleic acid packaging capability; 
2) the ability to overcome physiological barriers upon administration; and 3) effective 
cellular uptake and sub-cellular interactions [8]. As low transfection efficiency is the 
limiting factor of non-viral gene therapy vectors, the biological barriers involved in that 
process have to be analyzed in detail. Those include the plasma membrane with a plethora 
of internalization mechanisms governing the cellular homeostasis. In this sense, the size of 
the vehicle is of great relevance, being optimal between 30-50 nm [9,10] for rigid spherical 
particles, although cell internalization has been demonstrated for nanoparticles up to 200 
nm [11]. On the other hand, when this first barrier is overcome, the loaded endosomes have 
to face the fusion of lysosomes which often leads to the degradation of the vehicle and the 
cargo. Several viral-inspired peptides can be then included in the design of the vehicle to 
escape from this hurdle. At that time, if the cargo is intended to perform its function in the 
cytoplasm, no more biological barriers are encountered. However, if nucleus is the targeted 
cellular compartment, the presence of a nuclear localization signal may improve efficiency. 
Taking into account those considerations a novel generation of non-viral vectors is now 
under study, gaining attention for its performance in pre-clinical studies. Among the 
different types of delivery vehicles which can be decorated with functional moieties, 
recombinant proteins appear as a promising alternative due to the versatility in their design 
[12]. Being biocompatible molecules, proteins offer an almost infinite platform to obtain 
gene therapy vehicles with regulatable immunogenicity, adequate nanoscale size and 
specific functionalization. In addition, their production can be scaled up in cost effective 
expression systems from which they can be easily purified. In this context, we have designed 
a protein-based gene-therapy delivery vector by the thorough selection of four sequential 
functional domains. The N-terminal His-tag provides an endosomal escape moiety and also 
serves as an efficient purification tag [13]. The DNA-binding domain allows binding and 
condensation of expressible DNA for the formulation of the vector [14]. The third element 
is the human dynein light chain Rp3 [15]. Dyneins are motor-containing protein complexes 
formed by a heavy chain polypeptide interacting with several associated subunits that 
directly or indirectly load cargoes to be transported towards the microtubule organizing 
center (MTOC) [16]. The addition of Rp3 is expected to improve the intracellular movement 
of the vehicle towards the nucleus. Finally, a TAT inspired domain confers cell penetrating 
properties to the vehicle type [17]. TAT is a transcriptional transactivator of HIV which has 
been demonstrated to enter the cell via different mechanisms, which largely depend on the 
type of attached cargo and cell type [18–20]. In this work, the mechanisms behind the cell 
uptake and intracellular trafficking of the modular protein vector T-Rp3 are further 
analyzed. The ability to mimic viral infection capabilities is demonstrated at the microscopic 
level. Furthermore, the vector shown to be able to efficiently delivery not only large pDNA 
cargos, but also the much smaller siRNA molecules. This type of tuned and versatile 
recombinant protein is envisioned as a powerful alternative to the viral vectors for gene-
therapy purposes.  
 
2 MATERIALS AND METHODS 
2.1 Recombinant protein production 
The recombinant T-Rp3 was expressed in E. coli BL21 (DE3) and purified by a single step 
Ni-chelating affinity chromatography in an ÄKTA purifier FPLC (GE Healthcare) as 
previously described [20]. Protein was then dialyzed against 50 mM MES buffer (4-
Morpholineethanesulfonic acid hydrate) (pH 6.0) overnight at room temperature, frozen in 
liquid nitrogen and stored at -80 ºC after filtration through 0.22 μm pore membrane.  
 
2.2 Evaluation of DNA-protein interaction by Electrophoretic Mobility Shift Assay 
(EMSA) 
Protein-DNA complexes were formed using 1 µg of pTriEx-1.1 Hygro plasmid (Novagen) at 
different pDNA: protein molar ratios (1:100, 1:200, 1:500, 1:1000, 1:2000, 1:8000) during 
10 minutes in a final volume of 50 µL in 50 mM MES buffer pH 6.0. The increasing molar 
ratios were assessed by EMSA assay on a 0.8% agarose gel and visualized by ethidium 
bromide staining. For further experiments, all samples were prepared at 1:8000 
pDNA:protein molar ratio with 1 µg of pDNA and the corresponding amount of protein as 
described above. 
 
2.3 Transmission Electron Microscopy (TEM) 
Droplets of each sample (0.05 mg/mL or 0.1 mg/mL of protein, with or without pDNA) were 
deposited onto a carbon-coated copper grid for 5 min, and excess specimen was dried out 
with filter paper. Samples were submitted to negative staining with uranyl acetate and 
observed with a Jeol JEM 1400 transmission electron microscope, equipped with a CCD 
Gatan ES1000W Erlangshen camera. 
 
2.4 Dynamic Light Scattering 
Volume size distribution of protein nanoparticles and pDNA:protein complexes were 
measured using a dynamic light scattering (DLS) analyzer at a wavelength of 633 nm 
(Zetasizer Nano ZS, Malvern Instruments Limited). Samples were prepared as previously 
described for EMSA assays, where the corresponding amount of each molar ratio of protein 
is added to 1µg pDNA in a final volume of 50 µL in 50 mM MES buffer pH 6.0. Samples were 
incubated for 10 minutes, placed in the cuvette and measured at 25 ºC in triplicate, 
corresponding approximately to 10 minutes readings.  
 
2.5 Cell culture and laser scanning confocal microscopy (LSCM) 
HeLa cells were cultured in MEMα Glutamax (Gibco) supplemented with 10% fetal calf 
serum (Gibco), and incubated at 37 ºC and 5 % CO2 in a humidified atmosphere. For LSCM 
imaging, cells were grown on MatTek culture dishes (MatTek Corporation). The nuclei were 
labeled with 5 μg/mL Hoechst 33342 (Molecular Probes), lysosomes were labeled with 200 
nM LysoTracker® Red (Molecular Probes), and the plasma membranes with 5μg/mL 
CellMaskTM Deep Red (Molecular Probes) for 15 minutes in dark. The cells were then 
washed in phosphate-buffered saline (Sigma-Aldrich Chemie GmbH). Live cells were 
recorded by TCS LSCM (Leica Microsystems) equipped with Argon 488, DPSS 561, HeNe 
633 and Diode 405 lasers for the excitation of GFP and Atto 488 (Sigma Aldrich), 
LysoTracker and CellMask, Draq5 and Hoechst 3342, respectively. A Plan Apo 63 × /1.4 (oil 
HC × PL APO lambda blue) objective was used. To determine the localization of engulfed 
particles inside the cell, 0.29 μm sections were acquired and three-dimensional models 
were generated using Imaris 7.3.0 version software (Bitplane). The protein was labeled 
with Atto 488 according to manufacturer´s protocol and the plasmid was labeled with Draq5 
(Thermo Scientific) ahead of transfection, which resulted in mild labeling of the nuclei. In 
order to visualize microtubules, HeLa cells were prepared as described and transfected 24 
hours before microscopy imaging with pAcGFP1-Tubulin (Clontech) using Lipofectamine 
LTX (Invitrogen). pDNA:protein complexes were prepared as described above and added to 
complete-media-containing cell culture, and images were then taken 30 to 60 minutes after 
transfection.  
 
2.6 Transfection of HeLa cells 
For transfection assays, HeLa cells were transfected with pDNA T-Rp3 in the molar ratio 
1:8000 using GFP as reporter gene. Protein-DNA complexes were formed in 50 µL in 50 mM 
MES buffer pH 6.0 for 10 minutes. The mixture was the added to 24 well plates containing 
250 µL Optipro medium (Gibco) with cells at 70% confluency.Chloroquine 100 µM was 
added 2 hours pre-transfection in the presence of Optipro medium (Gibco). Control 
experiments were performed in the same conditions but without the addition of 
chloroquine. The medium was replaced 6 hours post-transfection and cell samples were 
analyzed 24 hours post-transfection after treatment with 1 mg/mL trypsin (Gibco) for 15 
minutes on a FACSCanto system (Becton Dickinson) using a 15 mW air-cooled argon ion 
laser at 488 nm excitation. Fluorescence emission was measured with a D detector (530/30 
nm band pass filter).  
 
2.7 Single Particle Tracking using FIJI (Image J) 
HeLa cells were grown as described for LSCM analysis. T-Rp3 labeled with Atto 488 was 
incubated with unlabeled pDNA for 10 minutes and then added to cell culture. 5 minutes 
later, the plasma membrane was labeled with 5 μg/mL CellMaskTM Deep Red (Molecular 
Probes) and the nuclei were labeled with 5 μg/mL Hoechst 33342 (Molecular Probes) for 
10 minutes before being washed in phosphate-buffered saline. Live cells were recorded by 
TCS-SP5 LSCM (Leica Microsystems) by taking images every 2 seconds for 5 minutes. 
Manual particle tracking was performed on FIJI distribution package [21] for 4 fast-moving 
particles.  
 
2.8 Gene silencing through iRNA 
For siRNA assays we used the luciferase system in HeLa cells, with single-stranded RNA 
sequences targeting the luciferase GL3 gene (Elbashir et al., 2001) (5’-
CUUACGCUGAGUACUUCGATT-3’ and 3’ – TTGAAUGCGACUCAUGAAGCU – 5’) synthesized 
(Sigma-Aldrich), solubilized in UltraPure DEPC-treated water to 1 mM and diluted to 40 μM 
in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH, 2 mM magnesium 
acetate; pH 7.4, DEPC-treated). Complementary strands were annealed for one minute at 
90˚C, followed by one hour at 37˚C in a PTC-200 Peltier Thermal Cycler. For the assay HeLa 
cells were transfected with 1μg/well of pVAX-LUC plasmid containing Luciferase gene 
(Toledo et al., 2012) using LipofectamineTM 2000 (Invitrogen) as transfection reagent, 
according to the manufacturer instructions. After 5 hours of incubation at 37 °C in 5% CO2 
humidified environment, the medium was replaced and cells were transfected with 40 or 
100 nM luciferase targeting dsRNA, using T-Rp3 or LipofectamineTM 2000 as control 
transfecting reagent (following manufacturer instructions). Cells were further incubated for 
6 hours at 37 °C in 5% CO2 humidified environment before the medium was replaced, and 
24 hours after the first transfection cells were collected and analyzed for luciferase activity 
using the Luciferase Assay System (Promega), following the manufacturer's instructions. 
Luminescence intensity was normalized by total protein concentration in each sample, 
which was determined with a Micro BCA Protein Assay Kit (Thermo Scientific). All assays 
were performed in triplicate. 
 
3 Results and Discussion 
3.1 Characterization of T-Rp3-DNA complexes 
T-Rp3 is a modular recombinant protein based on dynein light chain Rp3, to which 
a DNA binding domain, a histidine tag and a TAT peptide was added as previously described 
(Fig. 1A) [20]. This protein had been shown to efficiently transfect HeLa cells in a process 
dependent of the microtubule network, although the mechanism by which it takes place was 
still not unraveled [20]. The T-Rp3 protein used in this study was produced in E. coli and 
successfully purified by a single-step affinity chromatography. Through coomassie blue 
staining and western blot analysis using anti-his primary antibody, the recombinant protein 
was identified as a single band with no significant contaminant protein bands (Fig. 1B). The 
purified protein has a DNA-binding domain responsible for interacting with pDNA, thus 
different pDNA:protein molar ratios were used to induce the formation of complexes that 
were further analyzed by EMSA (Fig. 1C), indicating that at 1:500 molar ratio most of the 
pDNA is complexed with the protein. Since in previous reports the plasmid used had 4450 
bp [20], we evaluated here the protein’s capacity to equally condensate a larger plasmid, of 
6951bp. The pDNA was complexed to the protein at similar molar ratios, hence indicating 
that T-Rp3 capacity to interact with pDNA is maintained for larger plasmids. The effect of 
pDNA:protein molar ratios on the size and polydispersity of the generated nanoparticle was 
also evaluated, using dynamic light scattering (Fig. 1D-I).  As molar ratio increase, the 
complex’s size also increases, as well as the polydispersity, reaching over 900 nm at 1:500 
molar ratio, with a polydispersity index of 0.246 at this ratio. With the further addition of 
protein, the particle’s size begins to decrease at 1:1000, reaching 147.5 nm at 1:8000 molar 
ratio, with lower polydispersity (0.125). Since the protein is positively charged, it binds to 
pDNA resulting in an increase of size up to the neutrality point, after which the condensation 
process begins, leading to a reduction in size. Even though we had previously observed that 
the increase in the molar ratio positively impacts the transfection efficiency, until now we 
had been not able to correlate the internalization with the characteristics of the resulting 
nanoparticle formed at different ratios.  For further experiments, the 1:8000 molar ratio 
was used, as this is the condition in which the protein-DNA complexes were the smallest 
and the higher transfection efficiency achieved [20]. 
The protein alone as well as the complex formed by the protein with pDNA, were 
evaluated by transmission electron microscopy for the first time. Our previous findings 
using DLS measurements of the protein alone in solution consistently presented a high 
polydispersity index. However, the images obtained now using TEM show that T-Rp3 
presents the capacity to self assemble in small nanoparticles of toroidal shape (Fig. 2A-C), 
while some aggregates are also visible. In the presence of pDNA (Fig. 2D-F) we observed 
larger nanoparticles of a globular shape. Consistent with TEM images, DLS assays (Fig. 2G) 
indicated that protein alone forms nanoparticles of less than 10 nm, with a higher 
polydispersity, which is reduced in the presence of pDNA. This result was consistent with 
AFM images of Lc8-based protein interacting with pDNA [14]. A large number of proteins 
involved in DNA metabolism assume a toroidal structure, and this ring-shaped 
conformation is believed to facilitate the topological link to DNA [22]. Even protamine, a 
protein associated to DNA condensation in spermatogenesis and occasionally used as a gene 
delivery vector, forms toroid-shaped nanoparticles. This new evidence indicateed that the 
modular approach used to build the recombinant T-Rp3 allowed the development of a 
protein with self assembling capacity that mimics the toroidal conformation widely used in 
nature for DNA-binding. For instance, Western blotting analysis of extracts from Hela cell 
submitted to T-Rp3 protein (alone), T-Rp3-DNA, and T-Rp3-dsRNA transfection indicated 
that internalization occurs in all cases (data not shown), pointing to the versatility of uses 
of this modular vector. 
 
3.2 Intracellular trafficking of T-Rp3-DNA complexes 
Previous confocal microscopy images obtained for T-Rp3-DNA internalization gave 
indications that it could accumulate in the perinuclear region, in a pattern that differs from 
that of other delivery proteins, such as protamine [20]. However, those experiments were 
performed with fixed cells, and it is now well established that the fixation of cells may alter 
the internalization process, which is especially significant for cell penetrating peptides 
[Takeuchi and Futaki 2016]. For the aim of this study, LSCM imaging was performed on live 
HeLa cells, and for the first time the protein itself was fluorescently labeled, as well as the 
pDNA. Considering that size is regarded as an important feature affecting transfection 
efficiency, protein-DNA complexes formed with Atto 488-stained protein and DRAQ5-
stained plasmid were evaluated by dynamic light scattering and transmission electron 
microscopy. Results reveal that Atto 488 can promote a slight decrease in complex size, but 
the presence of Draq5 did not alter its size (Fig. 1 supplementary material). However, the 
presence of stain does not impair the formation of nanoparticles, as can be observed by 
TEM.  
A previous report suggested that T-Rp3 depends on microtubules network to 
accomplish gene delivery [20], although this hypothesis was still not confirmed by live 
particle tracking. In an attempt to better understand the intracellular trafficking mediated 
by T-Rp3 vector, the protein was previously stained with Atto 488 to evaluate the kinetics 
entrance in living HeLa cells. Images shown at Fig.3A indicated an accumulation of T-Rp3 
(in green) in a well-defined region in perinuclear area as soon as 30 minutes post-
transfection. This was consistent with delivery through microtubule since MTOC was 
usually located close to the cell nucleus [23]. Three-dimensional isosurface reconstructions 
from LSCM stack images of transfected cells (Fig. 3B-C) showed that the protein was actually 
located inside the cell, and occasionally trapped to nuclear membrane, with a small portion 
of it embedded in the nucleus. In the single particle tracking video supplied in 
supplementary material (video 1), the protein is stained in green and can be observed 
concentrated around the cells as soon as 15 minutes after being added to the medium, thus 
confirming how fast the internalization process takes place.   
Aiming to determine if the microtubule transport occurs by direct interaction of T-
Rp3 with dynein or if the accumulation is due to complexes transported inside endosomes, 
pDNA (stained with Draq5, seen in blue), T-Rp3 (stained with Atto488, in green) and late 
endosomes/lysosomes (stained with LysotrackerRed, in red) were observed inside live 
HeLa cells 30 minutes post transfection, when perinuclear accumulation was previously 
observed. Isosurface reconstructions indicated that all arrangements were present (Fig. 
4A), detecting free pDNA:T-Rp3 particles as well as trapped nanoparticles inside lysosomes. 
Non-complexed protein and pDNA-only particles were also observed. Sections of isosurface 
reconstructions (Fig. 4B-C) demonstrated the association of pDNA with T-Rp3 in protein 
nanoparticles contained in lysosomes or free in the cytosol. These results suggest that 
although part of the pDNA:T-Rp3 particles are retained inside endosomes, another part may 
be free to directly interact with molecular motors. As entrapment in acidic lysosomal 
compartments reduces transfection efficiency of gene therapy vectors, the detection of free 
pDNA:T-Rp3 particles might have a positive impact in this parameter [24]. For a more 
complete representation, please refer to the video 2 supplied in supplementary information. 
The fast perinuclear accumulation may be a result of an active transport being particles 
directly interacting with dynein, as well as travelling inside endo/lysosomes. Protamine-
containing nanoparticles which were entrapped in lysosomes, for instance, take up to 12 
hours to be internalized in vitro [25].  Unlike in previous experiments, in this case the fast 
internalization of T-Rp3 complexes could be followed in live cells using shorter incubation 
times.  
 
3.3 Tracking T-Rp3-DNA complexes movement along microtubules 
In order to analyze the effect of the endosomal entrapment of T-Rp3 nanoparticles, 
transfection experiments were performed in the presence of chloroquine, which is known 
to prevent lysosomal degradation due to acidification. In that case, transfection efficiency 
was increased from 15% to 23%, thus indicating that some particles actually remain 
trapped in endosomes (data not shown). To further evaluate microtubule participation in 
the traffic of T-Rp3 particles, HeLa cells were transfected with pAcGFP1-Tubulin 24 hours 
before microscopy so that microtubules could be observed in green. These cells were 
transfected with unstained T-Rp3 using pDNA previously stained with Draq5. As early as 30 
minutes post-transfection, most plasmids could be observed nearby microtubules (Fig. 5A). 
While most red dots are seen on green filaments, areas with no filaments tend to be plasmid-
free.  
Since naked pDNA poorly diffuses through cytoplasm [26–28], evaluating the 
particle speed inside the cell is an important indication of whether microtubule network is 
involved. Single particle tracking assays were performed on living HeLa cells, although the 
experiment was limited by the great speed of perinuclear accumulation, which restricted 
the use of 3D imaging in this case. On Fig. 5B, green dots representing pDNA:T-Rp3 are 
observed 15-30 minutes post transfection distributed inside the cell as well as attached to 
the cell membrane, as yellow dots indicates that the protein is embedded in cell membrane. 
Fig. 5C is a still from the video supplied in the online version of this article (Video 3, 
supplementary). The video is a 5-minutes-long particle tracking captured 30 minutes post-
transfection where particles move inside the cell in high speed, in linear displacements that 
stop and go, bidirectionally. From the video, four particles were manually tracked and their 
trajectories are highlighted in colors (the pink and the blue trails can be partially seen in the 
Fig. 5C), their speed being thus calculated and plotted (Fig. 5D). The speed varies along time, 
indicating that T-Rp3 is capable of exploiting microtubules in a similar approach to viruses, 
that also stop-and-go along microtubules [23].   
Surprisingly, single particle tracking images revealed a bidirectional movement 
(Video 3 in supplementary material)  which was also observed for viruses that exploit this 
strategy to move along microtubules [29,30]. To the best of our knowledge, this is the first 
report of a non viral vector that mimics this viral strategy to this extent. In vitro evaluation 
of molecular motors’ behavior when facing a microtubule intersection elucidated that 
dynein can overpass the intersection, move to another filament, and also reverse movement 
towards plus-end of microtubules, with an expected speed of 980 ± 70 nm/s for dyneins 
and 560 ± 30 nm/s for kinesins on nonintersecting microtubules [31]. The expected speed 
for dynein is compatible to the one observed for T-Rp3 particles (Fig. 5D), indicating that T-
Rp3 is capable of exploring molecular motors to accomplish intracellular trafficking. In 
previous experiments, the velocity of similar non-viral vectors whithout a dynein binding 
domain in transfection experiments had been calculated as 4.4 ± 0.3 nm/s, indicating an 
improvement in intracellular shuttle in the presence of such domain [32]. For polyplexes 
moving inside vesicles previous studies found an average speed of 0,19 µm/s [33]. Although 
dyneins essentially move towards the minus end of microtubules, previous reports indicate 
that about 30 % of dynein-dynactin runs are directed toward the plus ends of polarity-
marked microtubules [34]. T-Rp3 has already been reported to be highly dependent on 
microtubules to achieve efficient gene delivery, with transfection efficiency being reduced 
in 92 % in the presence of nocodazole, a microtubule depolymerizing agent [20]. These 
assays now reveal that pDNA:T-Rp3 particles are preferentially associated to microtubules 
and use the molecular motors to achieve high speed intracellular trafficking, thus efficiently 
mimicking viral particles that exploit microtubules to perform fast and bidirectional 
movement in a stop-and-go pattern.  
3.4 Delivery of dsRNA to Hela cells 
With the broadening of oligonucleotide-based approaches used in gene delivery 
assays, promising vectors are expected to have expanded capabilities as well. Since T-Rp3 
has previously shown to efficiently delivery plasmid DNA to HeLa cells, we evaluated the 
ability of this vector to delivery dsRNA, to be used in gene silencing experiments. Confirming 
previous Western blotting analysis that indicated cellular uptake of T-Rp3-dsRNA 
complexes, the results presented in Figure 6 show that T-Rp3 can achieve a performance in 
Luciferase silencing similar to that of the commercial lipid LipofectamineTM 2000. Even 
though LipofectamineTM 2000 is associated with high toxicity, it can still be considered a 
golden standard for transfection efficiency. Although the cytotoxicity of the T-Rp3-dsRNAi 
complexes were not assessed here, these results points to the versatile of this modular 
protein, presenting the ability to fast and efficiently delivery different nucleic acids cargos 
to cultured HeLa cells. 
 
 
Figure 6: Gene silencing of Luciferase expression in HeLa cells achieved by the delivery of 
40 and 100 nM dsRNA by either T-Rp3 or Lipofectamine TM 2000.  
 
4 Conclusions  
Engineering modular recombinant proteins is a feasible approach to address the 
several steps involved in protein internalization for gene delivery. Considering that viruses 
successfully exploit microtubule network, addressing this step may lead to nanoscale 
vectors that better mimic the viral counterparts. Physicochemical characterization of 
modular T-Rp3 protein alone showed for the first time the presence of toroidal structures 
that are observed in naturally-occurring DNA-interacting proteins, thus indicating how 
tunable proteins can be. In addition, T-Rp3 had been reported to efficiently transfect HeLa 
cells with low toxicity, but the extent of microtubule involvement remained unexplored and 
poorly characterized. Here, transfected live cells were analyzed by laser scanning confocal 
microscopy. The results indicate that T-Rp3 nanoparticles behave as fast-transfecting 
vectors that bind to cell membrane within minutes, and are further internalized to 
accumulate in localized regions of cytoplasm. In less than one hour, particles are already 
trapped to nuclear membrane, in a process much faster than other protein-based delivery 
vehicles.  Single particle tracking finally reveals that T-Rp3 not only is closely associated to 
microtubule in LSCM images, but also moves inside the cell with a motion pattern and speed 
compatible with a direct microtubule interaction, in a movement similar to those described 
to viral vectors.  Finally, the modular protein was found a versatile vehicle, being able to 
efficiently delivery different nucleic acids cargoes, including dsRNA, with an efficiency 
similar to that of the commercial vector LipofectamineTM 2000. 
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Figure legends  
 
Figure 1. Characterization of the recombinant protein T-Rp3 regarding its ability to 
condense DNA. (A) Coomassie blue-stained sodium dodecyl sulfate polyacrylamide 
electrophoresis (Co) and HisTag-based Western Blot immunodetection (WB) of protein 
purified after E. coli expression. (B) Schematic representation of the modular protein T-
Rp3. (C) Agarose gel retardation assay comparing increasing molar ratios of pDNA:T-Rp3, 
where molar ratios higher than 1:500 have the presence of shifted bands. (D-I) Dynamic 
light scattering results comparing the size distribution of particles formed in different 
molar ratios; first the size increases and then condensation effect takes place as size 
decreases with further addition of protein.  
 
Figure 2. Evaluation of T-Rp3 behavior regarding size in the presence of pDNA. (A-C) 
Transmission electron microscopy (TEM) images of the protein self-assembled in small 
nanoparticles; while some aggregates are present, T-Rp3 is observed assuming a toroidal 
conformation. (D-F) Transmission electron microscopy images of the pDNA:T-Rp3, 
particles of globular shape, together with some smaller aggregates. (G) Dynamic light 
scattering results in agreement with TEM images, indicating that the addition of pDNA 
promotes an increase in size and reduction in polydispersity.  
 
 
Figure 3. 3D LSCM images of live HeLa cells. (A) T-Rp3 (in green) is quickly internalized 
and accumulates in a specific area of the perinuclear region. (B and C) Sections of 3D 
reconstruction indicating that T-Rp3 is actually inside the cell, and as soon as 30 minutes 




Figure 4. 3D LSCM images of live HeLa cells. (A) Lysosomes (red), pDNA (blue) and T-Rp3 
(green) distribution inside the cells, where protein and pDNA can be observed inside 
lysosomes as well as free in the cytoplasm. (B and C) pDNA (blue) and T-Rp3 (green) 
observed attached together both inside and outside lysosomes (red). For further images 
please refer to the video available in the online version of the article. 
 
 
Figure 5. Assessment of T-Rp3 interaction with microtubules. (A) LSCM image showing 
pDNA (red) localization in relation to microtubules (green). (B) Within 30 minutes post 
transfection the protein (green) penetrates cellular membrane (colocalization with the 
membrane results in yellow dots) and reaches cytoplasm. (C) Still from the single particle 
tracking video (please refer to the video available in the online version) with the trajectory 
of two particles (pink and blue) highlighted (D) Analysis of the velocity of 4 individual 
fast-moving particles inside the cell. 
 
Supplementary material - Figure 1. Assessment of the effect of Atto 488 and DRAQ5 on 
nanoparticle formation. (A) Dynamic light scattering results comparing the size 
distribution of particles, showing that Atto488 can promote a slight decrease in particle 
size, while the addition of DRAQ5 has no effect.  (B) Transmission electron microscopy 
(TEM) images of the pDNA:T-Rp3-Atto 488 self-assembled in small nanoparticles. 
Supplementary material - Video 1. Single particle tracking video showing T-Rp3 (in 
green) accumulating around the cell and soon being internalized to reach perinuclear 
region. 
Supplementary material – Video 2. 3D LSCM images of live HeLa cells showing 
lysosomes (red), pDNA (blue) and T-Rp3 (green) distribution inside the cells, where 
protein and pDNA can be observed inside lysosomes as well as free in the cytoplasm. In 
the images pDNA and T-Rp3 are observed attached together both inside and outside 
lysosomes. 
Supplementary material – Video 3. Single particle tracking video showing T-
Rp3 (in green) traffic inside the cell. Four fast-moving particles were tracked and 
their trajectories where highlighted in colors.  
 
  
  
  
 
